Literature DB >> 88527

Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study.

P W Kohnen, G W Drach.   

Abstract

In a series of 162 cases of surgically resected hyperplastic prostates the incidence of inflammation is 98.1%. Six morphologic patterns of inflammation are described: 1) segregated glandular inflammation, 2) periglandular inflammation, 3) diffuse stromal inflammation, 4) isolated stromal lymphoid nodules, 5) acute necrotizing inflammation and 6) focal granulomatous inflammation. The most common pattern, segregated glandular inflammation, is characterized by intraluminal neutrophils and foamy macrophages and by chronic inflammatory cells in the surrounding stroma. No significant morphological differences are found among groups of cases with positive and negative evidence by culture of bacterial prostatic infection. Quantitative but not qualitative morphologic differences are found between cases of gram-negative infections and infection by gram-positive organisms that often are considered non-pathogens.

Entities:  

Mesh:

Year:  1979        PMID: 88527     DOI: 10.1016/s0022-5347(17)56980-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  46 in total

1.  The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis.

Authors:  Cuneyt Ozden; Ozdem Levent Ozdal; Ozer Guzel; Ozge Han; Selda Seckin; Ali Memis
Journal:  Int Urol Nephrol       Date:  2006-11-17       Impact factor: 2.370

2.  The picture of the prostatic lymphokine network is becoming increasingly complex.

Authors:  Georg E Steiner; Bob Djavan; Gero Kramer; Alessandra Handisurya; Martin Newman; Chung Lee; Michael Marberger
Journal:  Rev Urol       Date:  2002

Review 3.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

4.  Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism.

Authors:  Matthew B Rettig; David Heber; Jiabin An; Navindra P Seeram; Jian Y Rao; Huiren Liu; Tobias Klatte; Arie Belldegrun; Aune Moro; Susanne M Henning; Deqiong Mo; William J Aronson; Allan Pantuck
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 5.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

6.  Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.

Authors:  M Ishigooka; T Hashimoto; S Hayami; M Tomaru; T Nakada; K Mitobe
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 7.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

Review 8.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

Review 9.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

10.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.